DE602006019312D1 - Verfahren zur Vorhersage der Immunreaktion auf neoplastische Krankheiten auf der Grundlage des mRNA-Ausdrucksprofil in neoplastischen Zellen und stimulierten Leukozyten - Google Patents

Verfahren zur Vorhersage der Immunreaktion auf neoplastische Krankheiten auf der Grundlage des mRNA-Ausdrucksprofil in neoplastischen Zellen und stimulierten Leukozyten

Info

Publication number
DE602006019312D1
DE602006019312D1 DE602006019312T DE602006019312T DE602006019312D1 DE 602006019312 D1 DE602006019312 D1 DE 602006019312D1 DE 602006019312 T DE602006019312 T DE 602006019312T DE 602006019312 T DE602006019312 T DE 602006019312T DE 602006019312 D1 DE602006019312 D1 DE 602006019312D1
Authority
DE
Germany
Prior art keywords
tnf
cancer
leukocytes
chemokines
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006019312T
Other languages
English (en)
Inventor
Masato Mitsuhashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Showa Denko Materials Co ltd
Showa Denko Materials America Inc
Original Assignee
Hitachi Chemical Co Ltd
Hitachi Chemical Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hitachi Chemical Co Ltd, Hitachi Chemical Research Center Inc filed Critical Hitachi Chemical Co Ltd
Publication of DE602006019312D1 publication Critical patent/DE602006019312D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
DE602006019312T 2005-06-08 2006-06-08 Verfahren zur Vorhersage der Immunreaktion auf neoplastische Krankheiten auf der Grundlage des mRNA-Ausdrucksprofil in neoplastischen Zellen und stimulierten Leukozyten Active DE602006019312D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68874405P 2005-06-08 2005-06-08
US73550805P 2005-11-11 2005-11-11

Publications (1)

Publication Number Publication Date
DE602006019312D1 true DE602006019312D1 (de) 2011-02-10

Family

ID=37498782

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006019312T Active DE602006019312D1 (de) 2005-06-08 2006-06-08 Verfahren zur Vorhersage der Immunreaktion auf neoplastische Krankheiten auf der Grundlage des mRNA-Ausdrucksprofil in neoplastischen Zellen und stimulierten Leukozyten

Country Status (7)

Country Link
US (1) US7741023B2 (de)
EP (2) EP1964931B1 (de)
JP (1) JP4800384B2 (de)
CN (1) CN101194027B (de)
AT (2) ATE493515T1 (de)
DE (1) DE602006019312D1 (de)
WO (1) WO2006133399A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503206A (ja) * 2004-05-25 2008-02-07 日立化成工業株式会社 癌感受性を測定する方法
US20090011410A1 (en) * 2004-10-20 2009-01-08 Masato Mitsuhashi Method for tailoring administration of drugs by quantitation of mrna
WO2006116721A1 (en) * 2005-04-28 2006-11-02 Hitachi Chemical Research Center, Inc. Ex vivo gene expression in whole blood as a model of assessment of individual variation to dietary supplements
DE102007045562A1 (de) * 2007-09-24 2009-04-02 Robert Bosch Gmbh Steuereinrichtung für eine Anzeigeeinrichtung einer Einparkeinrichtung und Verfahren zur Darstellung
JP2011502535A (ja) 2007-11-14 2011-01-27 日立化成工業株式会社 末梢血白血球における、Ｆｃ受容体を介した腫瘍壊死因子スーパーファミリーｍＲＮＡ発現
EP3151005A1 (de) * 2009-08-28 2017-04-05 Astute Medical, Inc. Verfahren zur diagnose von nierenläsion und niereninsuffizienz
JP5706913B2 (ja) * 2009-12-16 2015-04-22 日立化成株式会社 攻撃的及び防御的免疫マーカーのｅｘｖｉｖｏ誘導により宿主免疫機能を特徴付けるための方法
EP2561368B1 (de) * 2010-04-19 2017-08-02 Biomarker Strategies, LLC. Zusammensetzungen und verfahren zur vorhersage von arzneimittelempfindlichkeit und -resistenz sowie krankheitsfortschritt
WO2012007783A1 (en) * 2010-07-13 2012-01-19 Institut Gustave Roussy Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject
WO2011131246A1 (en) * 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
WO2011131472A1 (en) * 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US8865653B2 (en) 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
JP2013528371A (ja) 2010-05-07 2013-07-11 日立化成株式会社 インターフェロン応答マーカーのエクスビボ誘導によるインターフェロンに対する宿主応答性を特徴づける方法
EP2388312A1 (de) * 2010-05-17 2011-11-23 Curetis AG Universell anwendbarer Lysepuffer und Verarbeitungsverfahren zur Lyse von Körperproben
WO2011156734A2 (en) 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Method of characterizing vascular diseases
WO2011156763A1 (en) 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Methods for characterizing kidney function
WO2012170037A1 (en) 2011-06-10 2012-12-13 Hitachi Chemical Co., Ltd. Vesicle capturing devices and methods for using same
WO2013012947A1 (en) * 2011-07-18 2013-01-24 Hitachi Chemical Co., Ltd. Methods of predicting host responsiveness to cancer immunotherapies by ex vivo induction of leukocyte-function-associated mrnas
US20140206574A1 (en) * 2011-08-31 2014-07-24 Karen Chapman Methods and Compositons for the Treatment and Diagnosis of Cancer
EP2893044A4 (de) * 2012-09-06 2016-04-27 Hitachi Chemical Co Ltd Verfahren zur beurteilung von peptidspezifischer immunität
JP2014057582A (ja) * 2012-09-17 2014-04-03 Hitachi Chemical Co Ltd 細胞傷害活性を予測するための方法及びキット
CN103193886A (zh) * 2013-04-14 2013-07-10 浙江大学 鼠抗人T细胞抗原ZCH-2B8a荧光标记单抗的用途
DE212013000295U1 (de) 2013-05-06 2016-02-02 Hitachi Chemical Co. America, Ltd. Vorrichtungen zum Einfangen von Zielmolekülen
CA2961340C (en) 2014-09-26 2023-10-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
US10266895B2 (en) 2014-11-05 2019-04-23 Hitachi Chemical Company Ltd. Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
JP6631852B2 (ja) 2014-11-12 2020-01-15 日立化成株式会社 臓器障害を診断するための方法および装置
JP6624704B2 (ja) 2015-08-31 2019-12-25 日立化成株式会社 尿路上皮疾患の評価のための分子法
CN109416925A (zh) * 2016-05-05 2019-03-01 南托米克斯有限责任公司 检查点失效和使检查点失效的方法
US20200041493A1 (en) * 2016-10-14 2020-02-06 StickyCell Pty Ltd Leukocyte adhesive function assays, devices and/or uses

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925572A (en) 1987-10-20 1990-05-15 Pall Corporation Device and method for depletion of the leukocyte content of blood and blood components
US4880548A (en) 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5491063A (en) 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
ES2347854T5 (es) 1996-03-26 2014-07-24 Michael S. Kopreski Método que permite el uso de RNA extracelular extraído de plasma o suero para detectar, monitorizar o evaluar un cáncer
US5683698A (en) 1996-08-02 1997-11-04 New England Deaconess Hospital Formulation for alleviating symptoms associated with arthritis
US7514232B2 (en) 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
US6183951B1 (en) 1997-04-11 2001-02-06 Prometheus Laboratories, Inc. Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy
US20020006613A1 (en) 1998-01-20 2002-01-17 Shyjan Andrew W. Methods and compositions for the identification and assessment of cancer therapies
AU768189B2 (en) 1999-06-15 2003-12-04 Nutri-Logics, Inc. Nutrient formulations for disease reduction, and related treatment and component screening methods
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6549616B1 (en) * 2000-03-20 2003-04-15 Serconet Ltd. Telephone outlet for implementing a local area network over telephone lines and a local area network using such outlets
US20020048566A1 (en) 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
US20020182274A1 (en) 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP1451340B1 (de) 2001-11-09 2014-01-08 Life Technologies Corporation Identifizierung, überwachung und behandlung einer krankheit sowie charakterisierung eines biologischen zustands unter verwendung von genexpressionsprofilen
AU2002352799A1 (en) 2001-11-20 2003-06-10 Oncomedx, Inc. Methods for evaluating drug-resistance gene expression in the cancer patient
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
FI20020078A (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6878518B2 (en) 2002-01-22 2005-04-12 The Trustees Of The University Of Pennsylvania Methods for determining steroid responsiveness
US7745180B2 (en) 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
WO2003099312A1 (en) 2002-05-27 2003-12-04 Östergötlands Läns Landsting Method for determining immune system affecting compounds
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
JP2008503206A (ja) 2004-05-25 2008-02-07 日立化成工業株式会社 癌感受性を測定する方法
WO2006110091A1 (en) 2005-04-15 2006-10-19 Therim Diagnostica Ab Diagnostic method for detecting cancer by measuring amount of a cytokine like il-6
WO2006116721A1 (en) 2005-04-28 2006-11-02 Hitachi Chemical Research Center, Inc. Ex vivo gene expression in whole blood as a model of assessment of individual variation to dietary supplements
CA2624359A1 (en) 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
WO2008106451A2 (en) 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease

Also Published As

Publication number Publication date
EP1904657A4 (de) 2008-12-31
EP1964931A2 (de) 2008-09-03
ATE510929T1 (de) 2011-06-15
JP4800384B2 (ja) 2011-10-26
WO2006133399A1 (en) 2006-12-14
EP1904657B1 (de) 2011-05-25
ATE493515T1 (de) 2011-01-15
EP1964931A3 (de) 2009-01-21
EP1904657A1 (de) 2008-04-02
JP2008543286A (ja) 2008-12-04
US7741023B2 (en) 2010-06-22
US20090111128A1 (en) 2009-04-30
WO2006133399A9 (en) 2007-03-01
CN101194027A (zh) 2008-06-04
EP1964931B1 (de) 2010-12-29
CN101194027B (zh) 2012-10-24

Similar Documents

Publication Publication Date Title
ATE493515T1 (de) Verfahren zur vorhersage der immunreaktion auf neoplastische krankheiten auf der grundlage des mrna-ausdrucksprofil in neoplastischen zellen und stimulierten leukozyten
Allavena et al. Pathways connecting inflammation and cancer
Reiland et al. CXC‐chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor
Liu et al. NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression
Schalper PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer
Solinas et al. Inflammation-mediated promotion of invasion and metastasis
Bertucci et al. The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers
Chen et al. The theory of tumor ecosystem
von Bergwelt-Baildon et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants
Carone et al. Immune gene expression profile in hepatocellular carcinoma and surrounding tissue predicts time to tumor recurrence
Russo et al. Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer
Liu et al. PD-1 related transcriptome profile and clinical outcome in diffuse gliomas
Li et al. A novel model based on necroptosis-related genes for predicting prognosis of patients with prostate adenocarcinoma
Zhao et al. Correlation between prognostic biomarker SLC1A5 and immune infiltrates in various types of cancers including hepatocellular carcinoma
Niu et al. Interleukin-17 gene polymorphisms contribute to cancer risk
Bai et al. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma
Munster et al. PI3K kinase inhibitor GSK2126458 (GSK458): Clinical activity in select patient (PT) populations defined by predictive markers (study P3K112826)
Knight et al. Prognostic factors in localized renal cell cancer.
Yokoigawa et al. Enhanced production of interleukin 6 in peripheral blood monocytes stimulated with mucins secreted into the bloodstream
Peter DICE: a novel tumor surveillance mechanism—a new therapy for cancer?
Zhou et al. Identifying common genes related to platelet and immunity for lung adenocarcinoma prognosis prediction
Chen et al. Role of cytokines and chemokines in alcohol-induced tumor promotion
Chiodin et al. High surface IgM levels associate with shorter response duration and bypass of the BTK blockade during ibrutinib therapy in CLL patients
Park et al. TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment
Cao et al. Expression of B7-H2 on CD8+ T cells in colorectal cancer microenvironment and its clinical significance